232 related articles for article (PubMed ID: 23706327)
1. Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population.
Fox K; Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Hennerici MG; Mattle HP; Rothwell PM;
Int J Cardiol; 2013 Oct; 168(4):3500-5. PubMed ID: 23706327
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study.
Hennerici MG;
Cerebrovasc Dis; 2009; 27 Suppl 3():28-32. PubMed ID: 19439938
[TBL] [Abstract][Full Text] [Related]
4. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox KM; Hennerici MG; Mattle HP; Rothwell PM; de Cordoüe A; Fratacci MD;
Lancet; 2011 Jun; 377(9782):2013-22. PubMed ID: 21616527
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Risk of Myocardial Infarction Compared to Recurrent Stroke After Transient Ischemic Attack and Ischemic Stroke: Systematic Review and Meta-Analysis.
Boulanger M; Béjot Y; Rothwell PM; Touzé E
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29348322
[TBL] [Abstract][Full Text] [Related]
6. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study.
Benn M; Nordestgaard BG; Jensen GB; Tybjaerg-Hansen A
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):661-70. PubMed ID: 17170368
[TBL] [Abstract][Full Text] [Related]
7. New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study.
Bang CN; Gislason GH; Greve AM; Bang CA; Lilja A; Torp-Pedersen C; Andersen PK; Køber L; Devereux RB; Wachtell K
J Am Heart Assoc; 2014 Jan; 3(1):e000382. PubMed ID: 24449803
[TBL] [Abstract][Full Text] [Related]
8. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici M; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(6):608-13. PubMed ID: 19407444
[TBL] [Abstract][Full Text] [Related]
9. PR interval prolongation in coronary patients or risk equivalent: excess risk of ischemic stroke and vascular pathophysiological insights.
Chan YH; Hai JJ; Lau KK; Li SW; Lau CP; Siu CW; Yiu KH; Tse HF
BMC Cardiovasc Disord; 2017 Aug; 17(1):233. PubMed ID: 28836952
[TBL] [Abstract][Full Text] [Related]
10. Stroke location and association with fatal cardiac outcomes: Northern Manhattan Study (NOMAS).
Rincon F; Dhamoon M; Moon Y; Paik MC; Boden-Albala B; Homma S; Di Tullio MR; Sacco RL; Elkind MS
Stroke; 2008 Sep; 39(9):2425-31. PubMed ID: 18635863
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
Young LH; Viscoli CM; Curtis JP; Inzucchi SE; Schwartz GG; Lovejoy AM; Furie KL; Gorman MJ; Conwit R; Abbott JD; Jacoby DL; Kolansky DM; Pfau SE; Ling FS; Kernan WN;
Circulation; 2017 May; 135(20):1882-1893. PubMed ID: 28246237
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial.
Hennerici MG; Bots ML; Ford I; Laurent S; Touboul PJ
Cardiovasc Drugs Ther; 2010 Apr; 24(2):175-80. PubMed ID: 20490906
[TBL] [Abstract][Full Text] [Related]
13. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.
Abtan J; Bhatt DL; Elbez Y; Sorbets E; Eagle K; Ikeda Y; Wu D; Hanson ME; Hannachi H; Singhal PK; Steg PG; Ducrocq G;
Clin Cardiol; 2016 Nov; 39(11):670-677. PubMed ID: 27588731
[TBL] [Abstract][Full Text] [Related]
14. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group.
Stroke; 1993 Apr; 24(4):543-8. PubMed ID: 8465360
[TBL] [Abstract][Full Text] [Related]
15. Effect of prompt revascularization on outcomes in diabetic patients with stable ischemic heart disease and previous myocardial infarction in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Chung MJ; Novak E; Brown DL
Coron Artery Dis; 2017 Jun; 28(4):301-306. PubMed ID: 28346285
[TBL] [Abstract][Full Text] [Related]
16. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register.
Nilsson PM; Cederholm J; Eeg-Olofsson K; Eliasson B; Zethelius B; Fagard R; Gudbjörnsdóttir S;
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):506-12. PubMed ID: 19561510
[TBL] [Abstract][Full Text] [Related]
17. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
18. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND.
Lonn EM; Rambihar S; Gao P; Custodis FF; Sliwa K; Teo KK; Yusuf S; Böhm M
Clin Res Cardiol; 2014 Feb; 103(2):149-59. PubMed ID: 24356937
[TBL] [Abstract][Full Text] [Related]
19. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
[TBL] [Abstract][Full Text] [Related]
20. A modified Essen stroke risk score for predicting recurrent cardiovascular events: development and validation.
Sumi S; Origasa H; Houkin K; Terayama Y; Uchiyama S; Daida H; Shigematsu H; Goto S; Tanaka K; Miyamoto S; Minematsu K; Matsumoto M; Okada Y; Sato M; Suzuki N
Int J Stroke; 2013 Jun; 8(4):251-7. PubMed ID: 22759563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
